TPCW
VKTX icon

TD Private Client Wealth’s Viking Therapeutics VKTX Stock Holding History

TD Private Client Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72K Hold
44
– – ﹤0.01% 1386
2026
Q1 		$1.43K Sell
44
-21
-32% -$675 ﹤0.01% 1336
2025
Q4 		$2.29K Buy
65
+28
+76% +$992 ﹤0.01% 1254
2025
Q3 		$972 Sell
37
-37
-50% -$1.1K ﹤0.01% 1338
2025
Q2 		$1.96K Buy
74
+62
+517% +$1.63K ﹤0.01% 1229
2025
Q1 		$290 Hold
12
– – ﹤0.01% 1363
2024
Q4 		$483 Buy
+12
New +$684 ﹤0.01% 1282

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TD Private Client Wealth's VKTX Position: Q2 2026 in Review

TD Private Client Wealth held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 44 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

TD Private Client Wealth first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.29K in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • TD Private Client Wealth held 44 shares of Viking Therapeutics worth $1.72K as of Q2 2026.
  • TD Private Client Wealth left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1386 holding.
  • TD Private Client Wealth first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • TD Private Client Wealth's Viking Therapeutics position peaked at $2.29K in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.